The company recently expanded its on-site testing capabilities at its Royston plant with a new analytical lab for both Rx and OTC drugs. The company is also expanding its production facility in Union, MO, with approximately 60,000 sq.-ft. of additional manufacturing space, which will be used primarily for the production of ingestible powders and will include a production room built to ISO8/100,000 clean room standards. The project is scheduled to be completed in 4Q14.
“During his tenure with Pharma Tech Industries, Byran has consistently demonstrated success managing a diverse roster of projects effectively,” said Tee Noland, chairman of Pharma Tech Industries. “As PTI continues to add new services and take on new customers, Bryan will play an instrumental role in leading the technological transfer process to ensure flawless execution during the hand off between sales and commercial production.”